BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 6.5%

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s stock price was up 6.5% on Monday . The stock traded as high as $6.61 and last traded at $6.58. Approximately 922,568 shares changed hands during trading, a decline of 74% from the average daily volume of 3,510,592 shares. The stock had previously closed at $6.18.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on BCRX shares. Needham & Company LLC reaffirmed a “buy” rating and set a $12.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. Finally, JMP Securities lifted their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a report on Tuesday, May 7th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $14.00.

BioCryst Pharmaceuticals Stock Performance

The business’s 50 day moving average is $5.78 and its 200-day moving average is $5.62. The stock has a market cap of $1.34 billion, a price-to-earnings ratio of -6.00 and a beta of 1.88.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The company had revenue of $92.80 million during the quarter, compared to analyst estimates of $85.62 million. During the same period in the prior year, the business posted ($0.28) EPS. BioCryst Pharmaceuticals’s revenue was up 34.9% compared to the same quarter last year. Sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.66 EPS for the current fiscal year.

Insiders Place Their Bets

In other BioCryst Pharmaceuticals news, CFO Anthony Doyle bought 36,300 shares of the stock in a transaction on Tuesday, May 14th. The shares were bought at an average price of $5.57 per share, with a total value of $202,191.00. Following the purchase, the chief financial officer now directly owns 266,744 shares in the company, valued at approximately $1,485,764.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other BioCryst Pharmaceuticals news, CFO Anthony Doyle bought 36,300 shares of the stock in a transaction on Tuesday, May 14th. The shares were bought at an average price of $5.57 per share, with a total value of $202,191.00. Following the purchase, the chief financial officer now directly owns 266,744 shares in the company, valued at approximately $1,485,764.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Steven K. Galson purchased 21,940 shares of BioCryst Pharmaceuticals stock in a transaction dated Monday, May 13th. The shares were bought at an average price of $5.49 per share, for a total transaction of $120,450.60. Following the acquisition, the director now owns 51,551 shares in the company, valued at $283,014.99. The disclosure for this purchase can be found here. Insiders have acquired a total of 103,601 shares of company stock valued at $596,338 in the last 90 days. 4.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Quarry LP purchased a new position in shares of BioCryst Pharmaceuticals during the 4th quarter worth $54,000. Seven Eight Capital LP purchased a new position in shares of BioCryst Pharmaceuticals during the 1st quarter worth $57,000. Natixis raised its holdings in BioCryst Pharmaceuticals by 400.6% in the 1st quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 9,350 shares during the period. Tower Research Capital LLC TRC raised its holdings in BioCryst Pharmaceuticals by 131.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,420 shares of the biotechnology company’s stock valued at $62,000 after buying an additional 5,912 shares during the period. Finally, JGP Global Gestao de Recursos Ltda. purchased a new stake in BioCryst Pharmaceuticals in the 4th quarter valued at about $64,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.